Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90

Acute B Lymphoblastic Leukemia (B-ALL) Clinical Trial

— HSP-HEMATO  

Official title:

Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04437420
• Other study ID #: GIRODON Collection 2020
• Status: Recruiting
• Start date: November 1, 2019
• Est. completion date: September 2021

Study information

• Verified date: June 2020
• Source: Centre Hospitalier Universitaire Dijon
• Contact: François GIRODON
• Phone: 0380295710
• Email: francois.girodon[@]chu-dijon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: September 2021
• Est. primary completion date: September 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform.

Exclusion Criteria:

• Patient over 80 years of age

Related Conditions & MeSH terms

• Acute B Lymphoblastic Leukemia (B-ALL)
• Acute T Lymphoblastic Leukemia (T-ALL)
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• injection of BEP 800
injection of BEP 800

Other:
• Control
no injection of BEP 800

Locations

Country	Name	City	State
France	Chu Dijon Bourgogne	Dijon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Viability on primary ALL samples	The effect of BEP-800 after 48 hours of treatment on T-ALL and B-ALL will be evaluated by counting viable cells by flow cytometry with a viability marker and specific antibodies to detect leukemia cells.	2 years
Secondary	Effect on SRC phosphorylation	The effect of BEP-800 on T-ALL and B-ALL will be evaluated by flow cytometry by measuring HSP90 and SRC (phosphorylated), by intracellular labeling after permeabilization of the cells, 18 hours after treatment with BEP-800.	2 years